NCT03420833Completed
Metabolic Mapping and Cardiac Resynchronization
Metabolic Mapping and Cardiac Resynchronization (Aim 1)
Source: ClinicalTrials.gov · Last updated 23 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle branch block (LBBB).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 82 (actual)
- First submitted
- 29 Jan 2018
- Start date
- 20 Aug 2018
- Primary completion date
- 19 Dec 2023
- Lead sponsor
- Yong-Mei Cha
- Diseases
- Heart failure
- NCT number
- NCT03420833
What you commit to
- Study type: Interventional
- Participants enrolled: 82
- From 20 Aug 2018 to the primary completion date, 19 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Female patients who is pregnant or not on a reliable form of birth control. Women of childbearing potential are required to have negative pregnancy test within the 7 days prior to device implant
Other illness
- Advanced comorbid conditions with life expectancy \<1 year
Age
- Patient is \<18 of years of age
Other
- Patient has a CRT device
- Unwilling or unable to return for required follow-up visits
- Patient decides study participation is cost-prohibited
Who the study is looking for
- Left Ventricular Ejection Fraction (LVEF) 35%-50%
- New York Heart Association (NYHA) class I-II
- QRS duration of ≥120ms
- Left bundle branch block (LBBB)
- Patient is able to receive a transvenous pectoral CRT implant
- Patient is able to sign informed consent
- Two echocardiograms are required to confirm a stable reduced LVEF
- Patient is on optimal and stable medical therapy (ACE inhibitor or angiotensin II type 1 (AT1 )blocker, beta blocker, etc. over the last 6 months)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.